We were delighted to attend the latest iNNovaciรณCSC debate, โ๐๐ป๐ป๐ผ๐๐ฎ๐๐ถ๐ผ๐ป ๐๐ผ ๐๐ฎ๐ฐ๐ธ๐น๐ฒ ๐๐ต๐ฒ ๐ฒ๐ฝ๐ถ๐ฑ๐ฒ๐บ๐ถ๐ฐ ๐ผ๐ณ ๐ป๐ฒ๐๐ฟ๐ผ๐ฑ๐ฒ๐ด๐ฒ๐ป๐ฒ๐ฟ๐ฎ๐๐ถ๐๐ฒ ๐ฑ๐ถ๐๐ฒ๐ฎ๐๐ฒ๐โ hosted by the Consorci de Salut i Social de Catalunya at the Parc Sanitari Pere Virgili.
The panel brought together a rich mix of profiles spanning science, industry, and patient and family care โ from network members Pablo Villoslada, Sรฒnia Abilleira, MD, PhD, and Laura Morer Benages to Eduardo Muรฑoz Roy, Associate Director โ Regional KAM at Lilly, who presented the laboratory and its research lines. Seeing these perspectives in dialogue was a real highlight.
Our thanks to Jordi Jordร Compaรฑรณ for giving us the floor to briefly introduce the NEUROAGE network.
Some o the key points disussed:
ยท The biggest opportunity sits between primary care and specialist diagnosis. Patients still wait months, sometimes years, for a diagnosis โ often after consulting several specialists first. ๐ฆ๐๐ฟ๐ฒ๐ป๐ด๐๐ต๐ฒ๐ป๐ถ๐ป๐ด ๐ฝ๐ฟ๐ถ๐บ๐ฎ๐ฟ๐ ๐ฐ๐ฎ๐ฟ๐ฒ’๐ ๐ฐ๐ฎ๐ฝ๐ฎ๐ฐ๐ถ๐๐ ๐๐ผ ๐ฑ๐ฒ๐๐ฒ๐ฐ๐ ๐ฒ๐ฎ๐ฟ๐น๐ ๐๐ถ๐ด๐ป๐ฎ๐น๐ ๐ฎ๐ป๐ฑ ๐๐๐ฟ๐ฒ๐ฎ๐บ๐น๐ถ๐ป๐ถ๐ป๐ด ๐ฟ๐ฒ๐ณ๐ฒ๐ฟ๐ฟ๐ฎ๐น ๐ฐ๐ถ๐ฟ๐ฐ๐๐ถ๐๐ ๐ถ๐ ๐๐ต๐ฒ๐ฟ๐ฒ ๐ถ๐บ๐ฝ๐ฎ๐ฐ๐ ๐ฐ๐ฎ๐ป ๐ฐ๐ผ๐บ๐ฒ ๐ณ๐ฎ๐๐๐ฒ๐๐.
ยท ๐ฃ๐ฟ๐ฒ๐๐ฒ๐ป๐๐ถ๐ผ๐ป ๐ถ๐ ๐ฏ๐ฒ๐ฐ๐ผ๐บ๐ถ๐ป๐ด ๐ฐ๐ฒ๐ป๐๐ฟ๐ฎ๐น. Reaching people before symptoms appear โ those worried about their risk, often after a family experience of Alzheimer’s or dementia โ opens the door to acting on modifiable risk factors and lifestyle changes that can meaningfully reduce future cognitive decline.
A valuable exchange on converting innovation into tangible clinical and patient benefits.
